Quality Assessment: Weak Long-Term Fundamentals
Sunil Healthcare’s quality rating remains subdued, reflecting its weak long-term fundamental strength. The company’s average Return on Capital Employed (ROCE) stands at a modest 5.21%, signalling limited efficiency in generating profits from its capital base. Over the past five years, net sales have grown at a sluggish annual rate of just 1.43%, indicating minimal top-line expansion in a competitive pharmaceuticals sector.
Moreover, the company’s ability to service debt is a concern, with a high Debt to EBITDA ratio of 5.63 times, suggesting elevated leverage and potential financial risk. Although the latest half-year data shows some improvement — with a Debt-Equity ratio reduced to 0.88 times and ROCE rising to 6.69% — these figures remain below industry averages, underscoring persistent structural weaknesses.
Sunil Healthcare’s profitability metrics also reflect challenges, with a Return on Equity (ROE) of only 2.55% and a latest half-year PAT of ₹1.59 crores. These figures highlight the company’s struggle to deliver robust shareholder returns despite recent positive quarterly earnings.
Our latest monthly pick, this Large Cap from Aluminium & Aluminium Products, is outperforming the market! See the analysis that helped our Investment Committee select this winner.
- - Market-beating performance
- - Committee-backed winner
- - Aluminium & Aluminium Products standout
Valuation: Upgrade to Attractive but Still Cautious
The valuation grade for Sunil Healthcare has improved from Very Attractive to Attractive, reflecting a more balanced view of its price metrics relative to peers. The company currently trades at a Price-to-Earnings (PE) ratio of 24.74, which, while higher than some competitors like Bliss GVS Pharma (PE 21.22), remains reasonable given its sector context.
Other valuation multiples include an Enterprise Value to EBITDA (EV/EBITDA) ratio of 9.24 and an Enterprise Value to Capital Employed ratio of 1.02, both signalling a discount compared to many peers classified as expensive or very expensive. The company’s PEG ratio is notably low at 0.09, indicating that its price is low relative to expected earnings growth, which is a positive sign for value investors.
However, the company’s Return on Capital Employed (ROCE) of 5.00% and Return on Equity (ROE) of 2.55% temper enthusiasm, as these returns are modest and suggest limited operational efficiency. Dividend yield data is not available, which may reduce appeal for income-focused investors.
Financial Trend: Mixed Signals Amid Recent Positives
Sunil Healthcare’s recent financial performance has shown some encouraging signs, with positive results reported for four consecutive quarters. The latest half-year PAT of ₹1.59 crores represents a significant 275.5% increase in profits over the past year, despite the stock price declining by 10.39% during the same period.
Despite this profit growth, the company’s stock has underperformed broader benchmarks such as the BSE500 and Sensex over multiple time frames. For instance, the stock returned -10.39% over the last year compared to the Sensex’s 9.66% gain, and over three years, it delivered 10.40% against the Sensex’s 35.81%. This underperformance highlights investor scepticism about the company’s growth prospects and market positioning.
Long-term growth remains weak, with net sales increasing at a mere 1.43% annually over five years, and the company’s ability to manage debt remains a concern despite recent improvements in leverage ratios.
Technicals: Downgrade to Bearish Outlook
The most significant factor driving the downgrade to Strong Sell is the deterioration in technical indicators. The technical grade has shifted from mildly bearish to bearish, reflecting a more negative market sentiment and momentum.
Key technical signals include a bearish Moving Average Convergence Divergence (MACD) on both weekly and monthly charts, and daily moving averages also indicate a bearish trend. Bollinger Bands show mild bearishness on weekly and monthly timeframes, while the Relative Strength Index (RSI) presents a mixed picture with no signal weekly but a bullish monthly reading.
The Know Sure Thing (KST) indicator is mildly bullish weekly but bearish monthly, and Dow Theory analysis shows no clear trend on either timeframe. The On-Balance Volume (OBV) data is inconclusive, adding to the uncertainty.
Price action remains subdued, with the stock currently trading at ₹69.00, close to its 52-week low of ₹60.55 and well below its 52-week high of ₹88.70. The stock’s one-week return of 1.80% slightly outperformed the Sensex’s -0.94%, but longer-term returns remain negative.
Sunil Healthcare Ltd or something better? Our SwitchER feature analyzes this micro-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Comparative Performance and Market Context
Sunil Healthcare operates within the Pharmaceuticals & Biotechnology sector, a space characterised by rapid innovation and intense competition. When benchmarked against peers, the company’s valuation metrics appear attractive, but its operational and financial metrics lag behind.
For example, Bliss GVS Pharma, a peer with a fair valuation, trades at a PE of 21.22 and EV/EBITDA of 15.63, while Shukra Pharma is considered very expensive with a PE of 63.22. Sunil Healthcare’s valuation thus sits in a more moderate range, but its weak returns and high leverage undermine investor confidence.
Over the past decade, Sunil Healthcare’s stock has delivered a negative 23.59% return, starkly contrasting with the Sensex’s 259.08% gain, highlighting the company’s underperformance in the broader market context.
Outlook and Investor Considerations
While Sunil Healthcare has demonstrated some recent financial improvements and an attractive valuation profile, the downgrade to Strong Sell reflects a cautious stance driven by bearish technicals and weak long-term fundamentals. Investors should weigh the company’s modest profitability, high leverage, and underwhelming growth against its valuation discount and recent profit growth.
Given the mixed signals, the stock may remain volatile, and investors seeking exposure to the pharmaceuticals sector might consider alternatives with stronger financial health and more positive technical momentum.
Shareholding and Market Capitalisation
The company’s majority shareholding remains with promoters, maintaining stable ownership structure. Sunil Healthcare’s market capitalisation grade is rated 4, reflecting its micro-cap status within the sector.
On 17 Feb 2026, the stock closed at ₹69.00, up 1.47% from the previous close of ₹68.00, but still below its 52-week high of ₹88.70, underscoring the ongoing challenges in regaining investor confidence.
Summary of Rating Changes
The investment rating downgrade from Sell to Strong Sell on 16 Feb 2026 was primarily triggered by a shift in technical indicators from mildly bearish to bearish, signalling increased downside risk. The valuation grade improved from very attractive to attractive, reflecting a more balanced price perspective, but this was insufficient to offset concerns over quality and financial trends.
Overall, the company’s Mojo Score stands at 29.0, with a Mojo Grade of Strong Sell, indicating a cautious outlook for investors.
Unlock special upgrade rates for a limited period. Start Saving Now →
